ERAS Erasca, Inc.

$18.38

Erasca, Inc. (ERAS) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $0.13 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.3% since its last earnings release on August 11, 2026.

Erasca Missed Consensus Estimates
Tuesday, August 11, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 4:00 PM ET
Earnings Whisper
-
vs ($0.13)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $18.31

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Erasca, Inc.

Erasca Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Erasca Inc. is based in SAN DIEGO.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow